A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer

被引：0
|
作者：
Clarke, S. J. [1 ,2 ,3 ]
Smith, J. T. [1 ,2 ,3 ]
Gebbie, C. [1 ,2 ,3 ]
Sweeney, C. [1 ,2 ,3 ]
Olszewski, N. [1 ,2 ,3 ]
机构：
[1] Alder Biopharmaceut Inc, Bothell, WA USA
[2] Sydney Canc Ctr, Sydney, NSW, Australia
[3] Univ Adelaide, Adelaide, SA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3025
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CONTINUOUS AND INTERMITTENT VORINOSTAT (V) IN COMBINATION WITH FOLFIRI IN ADVANCED UPPER GASTROINTESTINAL CANCER (AUGC): PRELIMINARY RESULTS OF A PHASE I PHARMACOKINETIC (PK) STUDY
    Khushalani, N. I.
    Brady, W.
    Fetterly, G.
    Prey, J.
    Levea, C.
    Litwin, A.
    Grande, C.
    Iyer, R.
    Javle, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 260 - 260
  • [42] Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
    Oaknin, A.
    Ellard, S. L.
    Leath, C., III
    Moreno, V.
    Kristeleit, R.
    Guo, W.
    Lu, S.
    Jenkins, D.
    McEachern, K.
    Jen, K. Yu
    Dunlap, S.
    Im, E.
    Gilbert, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 334 - 334
  • [43] A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) plus Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients
    Vo, A.
    Choi, J.
    Cisneros, K.
    Kahwaji, J.
    Toyoda, M.
    Bongha, S.
    Ge, S.
    Peng, A.
    Villicana, R.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 103 - 103
  • [44] A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer
    Camidge, D.
    Herbst, R. S.
    Gordon, M.
    Eckhardt, S.
    Kurzroc, R.
    Durbin, B.
    Ing, J.
    Ling, J.
    Sager, J.
    Mendelson, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] A Phase I/II Trial of Tocilizumab (Anti-IL-6 Receptor) plus Intravenous Immunoglobulin (IVIG) for Desensitization (DES) in Difficult to DES Patients
    Vo, A.
    Choi, J.
    Cisneros, K.
    Kahwaji, J.
    Toyoda, M.
    Bongha, S.
    Ge, S.
    Peng, A.
    Villicana, R.
    Jordan, S.
    TRANSPLANTATION, 2014, 98 : 103 - 103
  • [46] A first-in-human phase I study of SAR650984, a humanized anti-CD38 antibody in patients with CD38+hematological malignancies: Preliminary PK and PD results of escalation phase
    Ozoux, Marie-Laure L.
    Guillemin, Helene
    Pascual, Marie-Helene H.
    Cartot-Cotton, Sylvaine
    Veyrat-Follet, Christine
    Valente, Delphine
    Moulard, Maxime
    Mauriac, Christine
    Deslandes, Antoine
    Semiond, Dorothee
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: Results from a 24 week double-blind phase III study
    Nishimoto, N.
    Miyasaka, N.
    Yamamoto, K.
    Kawai, S.
    Takeuchi, T.
    Azuma, J.
    Kishimoto, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 59 - 59
  • [48] Phase I clinical study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody (Nimotuzumab) in combination with chemotherapy in patients with locally-advanced breast cancer.: Preliminary results
    Soriano, J.
    Batista, N.
    Lima, M.
    Rodriguez, R.
    Lopez, M. V.
    Montenegro, A.
    Ramos, M.
    Rodriguez, L.
    Garcia, R.
    Rodriguez, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 116 - 117
  • [49] A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies
    Shah, Nirav N.
    Krishnan, Amrita Y.
    Shah, Nina D.
    Burke, John M.
    Melear, Jason M.
    Spira, Alexander I.
    Kaufman, Jonathan L.
    Cohen, Jonathon B.
    Niesvizky, Ruben
    Popplewell, Leslie L.
    Chhabra, Saurabh
    Sharman, Jeff P.
    Martin, Thomas G.
    Matheny, Shannon L.
    Leonard, John P.
    Molina, Arturo
    CANCER RESEARCH, 2019, 79 (13)
  • [50] Consistent clinical response resulted from three Japanese randomized controlled trials of tocilizumab, humanized anti-IL-6 receptor antibody, in active rheumatoid arthritis (RA) patients.
    Nishimoto, Norihiro
    Miyasaka, Nobuyuki
    Yamamoto, Kazuhiko
    Kawai, Shinichi
    Takeuchi, Tsutomu
    Azuma, Junichi
    Kishimoto, Tadamitsu
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S410 - S410
12345